Yuan Marshall, Wassef Andrew, Sargsyan Davit, Nersisyan Vahe, Cabrera Javier, Nahass Ronald G, Hassan Wael, Kong Ah-Ng, Brunetti Luigi
Robert Wood Johnson Medical School, Piscataway, New Jersey, USA.
Department of Pharmaceutics, Ernest Mario School of Pharmacy, Piscataway, New Jersey, USA.
J Med Virol. 2025 Jun;97(6):e70425. doi: 10.1002/jmv.70425.
Severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) presents with a diverse symptomology, ranging from asymptomatic to severe disease, but the mechanism of risk factors such as diabetes remains unelucidated. The current retrospective cohort study of 182 patients, with and without COVID-19 and diabetes, analyzed leftover blood specimens for RNA sequencing and chemokine/cytokine, ACE2/DPP-IV concentrations. After analysis, 14 223 genes had sufficient hits; 18 genes and 431 genes were differentially expressed between patients with and without COVID-19 and patients with and without diabetes, respectively. Both analyses had differentially expressed five genes, GRASP, KRT8, MYZAP, PRKG1, and SMIM24. DPP-IV concentrations were statistically lower in COVID-19 patients versus non-COVID-19, but no significant differences in chemokine/cytokine expression and ACE2 concentrations were detected. This study provides insight into altered gene expression patterns in individuals with COVID-19 with and without diabetes mellitus and highlights potential markers for severe disease and pathways for treatment targets.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)表现出多种多样的症状,从无症状到重症疾病,但糖尿病等危险因素的机制仍未阐明。目前这项针对182例有或无2019冠状病毒病(COVID-19)及糖尿病患者的回顾性队列研究,分析了留存的血液标本以进行RNA测序以及趋化因子/细胞因子、血管紧张素转换酶2(ACE2)/二肽基肽酶4(DPP-IV)浓度检测。分析后,有14223个基因有足够的命中数;有或无COVID-19的患者之间以及有或无糖尿病的患者之间分别有18个基因和431个基因差异表达。两项分析均有5个差异表达基因,即GRASP、角蛋白8(KRT8)、肌动蛋白结合蛋白(MYZAP)、蛋白激酶G1(PRKG1)和小分子膜内在蛋白24(SMIM24)。COVID-19患者的DPP-IV浓度在统计学上低于非COVID-19患者,但未检测到趋化因子/细胞因子表达和ACE2浓度有显著差异。本研究深入了解了有或无糖尿病的COVID-19患者基因表达模式的改变,并突出了重症疾病的潜在标志物以及治疗靶点的途径。